医药代表篡改基因检测报告骗取医保被判刑

Core Points - A pharmaceutical representative from a certain company was sentenced for fraud after altering patient genetic test reports to meet sales targets, leading to misuse of targeted cancer medication and resulting in a loss of 27,540 yuan from the medical insurance fund [1][2] Group 1: Legal Proceedings - The court found that the representative's actions constituted fraud under Article 266 of the Criminal Law of the People's Republic of China, as he aimed to illegally occupy state medical insurance funds [2] - The representative was sentenced to eight months in prison and fined 7,000 yuan, with a requirement to return the illegal gains to the medical insurance fund [2] Group 2: Industry Implications - The case highlights the critical importance of adhering to drug usage guidelines, particularly for targeted cancer therapies, which require strict compliance with indications and genetic mutation conditions to ensure effective treatment [2] - The incident serves as a warning to the industry about the severe consequences of violating ethical standards and regulations, emphasizing that crossing legal boundaries can lead to significant legal repercussions [2]